Back to Search Start Over

Atypical antidepressant mirtazapine inhibits 5-hydroxytryptamine3 receptor currents in NCB-20 cells.

Authors :
Park YS
Oh H
Sung KW
Source :
Journal of pharmacological sciences [J Pharmacol Sci] 2023 Feb; Vol. 151 (2), pp. 63-71. Date of Electronic Publication: 2022 Dec 05.
Publication Year :
2023

Abstract

Mirtazapine, an atypical antidepressant, is known to enhance serotonergic transmission by inhibiting the 5-hydroxytryptamine (5-HT) <subscript>1A</subscript> , 5-HT <subscript>2C</subscript> , and 5-HT <subscript>3</subscript> receptors. However, the mechanism of action on the 5-HT <subscript>3</subscript> receptor remains unclear. We investigated the inhibitory mechanisms of mirtazapine on 5-HT <subscript>3</subscript> receptors of NCB20 neuroblastoma cells using the whole-cell voltage-clamp method. Mirtazapine inhibited the 5-HT <subscript>3</subscript> receptor currents in a concentration-dependent manner, and the inhibitory effect was influenced by the concentration of 5-HT. When mirtazapine was co-applied to 5-HT, the maximal response of the 5-HT <subscript>3</subscript> receptor current was reduced and EC <subscript>50</subscript> was increased, suggesting that mirtazapine might act as a non-competitive inhibitor. Inhibition of 5-HT <subscript>3</subscript> current by mirtazapine was stronger in pre-application than in co-application, which suggests that mirtazapine might act as a closed state inhibitor. This finding was further supported by no use-dependency of the mirtazapine for 5-HT <subscript>3</subscript> receptor inhibition. Finally, mirtazapine accelerated the desensitization and deactivation process in a concentration-dependent manner. The difference in recovery time showed that mirtazapine drastically influences the desensitization process than the deactivation process. These mechanistic characteristics of mirtazapine support the understanding of the relationship between the 5-HT <subscript>3</subscript> receptor and atypical antidepressants.<br />Competing Interests: Declaration of competing interest The authors indicated no potential conflicts of interest.<br /> (Copyright © 2022 The Authors. Production and hosting by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1347-8648
Volume :
151
Issue :
2
Database :
MEDLINE
Journal :
Journal of pharmacological sciences
Publication Type :
Academic Journal
Accession number :
36707180
Full Text :
https://doi.org/10.1016/j.jphs.2022.12.002